Hydroxymethylglutaryl-CoA Reductase Inhibitors

"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Descriptor ID

D019161

MeSH Number(s)

D27.505.519.186.071.202.370

D27.505.519.389.370

D27.505.954.557.500.202.370

Concept/Terms

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Anticholesteremic Agents [D27.505.519.186.071.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.186.071.202.370]
Enzyme Inhibitors [D27.505.519.389]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]
Anticholesteremic Agents [D27.505.954.557.500.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.954.557.500.202.370]

Below are MeSH descriptors whose meaning is related to "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Harvard Catalyst Profiles by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publication.

Bar chart showing 1529 publications over 28 distinct years, with a maximum of 141 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	0	1	1
1993	1	0	1
1994	1	3	4
1995	0	1	1
1997	1	0	1
1998	7	1	8
1999	3	1	4
2000	12	6	18
2001	16	4	20
2002	28	4	32
2003	29	12	41
2004	31	10	41
2005	48	4	52
2006	45	25	70
2007	52	15	67
2008	42	25	67
2009	51	13	64
2010	57	20	77
2011	71	27	98
2012	70	21	91
2013	76	22	98
2014	92	25	117
2015	108	33	141
2016	65	40	105
2017	86	29	115
2018	86	27	113
2019	49	24	73
2020	7	2	9

Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.

Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, Galloway A, Vassy JL, Forman DE, Gaziano JM, Gagnon DR, Wilson PWF, Cho K, Djousse L. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. JAMA. 2020 07 07; 324(1):68-78.

View in: PubMed
Abramson J, Furberg C, Jewell N, Wright JM. Questioning statin therapy for older patients. Lancet. 2020 06 13; 395(10240):1831-1832.

View in: PubMed
Libby P. Statin drugs might boost healthy gut microbes. Nature. 2020 05; 581(7808):263-264.

View in: PubMed
White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c
View in: PubMed
Chasman DI, Giulianini F, Demler OV, Udler MS. Pleiotropy-Based Decomposition of Genetic Risk Scores: Association and Interaction Analysis for Type 2 Diabetes and CAD. Am J Hum Genet. 2020 05 07; 106(5):646-658.

View in: PubMed
Santos DM, Pantano L, Pronzati G, Grasberger P, Probst CK, Black KE, Spinney JJ, Hariri LP, Nichols R, Lin Y, Bieler M, Seither P, Nicklin P, Wyatt D, Tager AM, Medoff BD. Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis. Am J Respir Cell Mol Biol. 2020 04; 62(4):479-492.

View in: PubMed
Brånvall E, Ekberg S, Eloranta S, Wästerlid T, Birmann BM, Smedby KE. Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. Am J Hematol. 2020 06; 95(6):652-661.

View in: PubMed
Seamon K, Sanfilippo F, Bulsara M, Roughead L, Kemp-Casey A, Bulsara C, Watts GF, Preen D. Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study. Public Health Res Pract. 2020 Mar 10; 30(1).

View in: PubMed
Rogers AJ, Desai M, Matthay MA, Choi AM, Baron RM. The authors reply. Crit Care Med. 2020 01; 48(1):e78.

View in: PubMed
Panozzo CA, Curtis LH, Marshall J, Fine L, Wells BL, Brown JS, Haynes K, Pawloski PA, Hernandez AF, Malek S, Syat B, Platt R. Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. PLoS One. 2019; 14(12):e0223515.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Circulation
Am J Cardiol
J Am Coll Cardiol
JAMA
N Engl J Med
Atherosclerosis
Am Heart J
Lancet
Eur Heart J
Pharmacoepidemiol Drug Saf